{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:02:56Z","timestamp":1789588976499,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The pursuit of sustainability in analytical chemistry is a multifaceted, challenging and complex endeavor. This requires continuous and competitive attempts to achieve the sustainable development goals at every step of the analytical methodology by adhering to the principles of green, blue and white analytical chemistry. This also involves assessment of the degree of sustainability using the latest evaluation metrics until finally reaching the design of a trichromatic procedure. The herein illustrated work represents a comparative study between two newly developed normal-phase and reverse-phase HPTLC methods for the simultaneous quantitative determination of Remdesivir (RMD), Favipiravir (FAV) and Molnupiravir (MOL). For normal-phase HPTLC method, the employed mobile phase consisted of ethyl acetate: ethanol: water (9.4:0.4:0.25, v\/v), while, for reverse-phase HPTLC procedure, a greener mobile phase was employed consisting of ethanol: water (6:4, v\/v). For both methods, detection wavelength of RMD and MOL was 244\u00a0nm while FAV was detected at 325\u00a0nm. Both methods were validated following the International Council for Harmonisation (ICH) guidelines with respect to linearity, range, accuracy, precision and robustness. The two established methods were proved to be linear over the range of 50-2000 ng\/band for FAV and MOL and over the range of 30\u2013800 ng\/band for RMD. The excellent linearities were proved by the high values of correlation coefficients not less than 0.99988. The developed methods were successfully applied for the determination of the three drugs in their bulk form and in their pharmaceutical formulations. Furthermore, a thorough comparative and integrative trichromatic evaluation of sustainability of the designed methods was performed. The Analytical Eco-Scale, the novel Modified Green Analytical Procedure Index (MoGAPI) (2024) and the Analytical GREEnness (AGREE) metrics were applied for greenness assessment and the recent Blue Applicability Grade Index (BAGI) (2023) tool was employed for blueness evaluation. Finally, the RGB12 model was implemented for appraisal of whiteness of the developed methods.<\/jats:p>","DOI":"10.1186\/s13065-025-01439-9","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T09:47:53Z","timestamp":1743241673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative study of Normal-phase versus reversed-phase HPTLC methods for the concurrent quantification of three antiviral agents against COVID19: Remdesivir, favipiravir and Molnupiravir: trichromatic sustainability assessment"],"prefix":"10.1186","volume":"19","author":[{"given":"Dina Salah","family":"El-Kafrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira H.","family":"Abo-Gharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1439_CR1","doi-asserted-by":"publisher","unstructured":"Nowak PM, Wietecha-Pos\u0142uszny R, Pawliszyn J. White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality. TRAC Trends Anal Chem. 2021;116223. https:\/\/doi.org\/10.1016\/j.trac.2021.116223.","DOI":"10.1016\/j.trac.2021.116223"},{"issue":"19","key":"1439_CR2","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi N, Wojnowski W, P\u0142otka-Wasylka J, Samanidou V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 2023;25(19):7598\u2013604. https:\/\/doi.org\/10.1039\/D3GC02347H.","journal-title":"Green Chem"},{"key":"1439_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","volume":"15","author":"J Machhi","year":"2020","unstructured":"Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, Blomberg WR, Meigs DD, Hasan M, Patel M. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020;15:359\u201386. https:\/\/doi.org\/10.1007\/s11481-020-09944-5.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"5","key":"1439_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672\u201383. https:\/\/doi.org\/10.1021\/acscentsci.0c00489.","journal-title":"ACS Cent Sci"},{"key":"1439_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","volume":"41","author":"MP Lythgoe","year":"2020","unstructured":"Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41:363\u201382. https:\/\/doi.org\/10.1016\/j.tips.2020.03.006.","journal-title":"Trends Pharmacol Sci"},{"key":"1439_CR6","unstructured":"Food US, Drug Administration FDA. FDA\u2019s Approval of Veklury (Remdesivir) for the Treatment of COVID-19, 2020, October 22. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness"},{"key":"1439_CR7","doi-asserted-by":"publisher","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Gotte M. \u00a8Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785\u201397. https:\/\/doi.org\/10.1074\/jbc.RA120.013679.","DOI":"10.1074\/jbc.RA120.013679"},{"key":"1439_CR8","doi-asserted-by":"crossref","unstructured":"Du Y-X, Chen X-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020;108(2):242\u20137. https:\/\/doi.org\/10.1002\/cpt.1844.","DOI":"10.1002\/cpt.1844"},{"issue":"3","key":"1439_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/aac.49.3.981-986.2005","volume":"49","author":"Y Furuta","year":"2005","unstructured":"Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981\u20136. https:\/\/doi.org\/10.1128\/aac.49.3.981-986.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107512.","journal-title":"Pharmacol Ther"},{"key":"1439_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","volume":"73","author":"AA Ivashchenko","year":"2020","unstructured":"Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II\/III multicenter randomized clinical trial. Clin Infect Dis. 2020;73:531\u20134. https:\/\/doi.org\/10.1093\/cid\/ciaa1176.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1439_CR12","doi-asserted-by":"publisher","first-page":"e13732","DOI":"10.1111\/cts.13732","volume":"17","author":"BM Maas","year":"2024","unstructured":"Maas BM, Strizki J, Miller RR, Kumar S, Brown M, Johnson MG, Cheng M, De Anda C, Rizk ML, Stone JA, Molnupiravir. Mechanism of action, clinical, and translational science. Clin Transl Sci CTS. 2024;17(2):e13732. https:\/\/doi.org\/10.1111\/cts.13732.","journal-title":"Clin Transl Sci CTS"},{"issue":"1","key":"1439_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","volume":"21","author":"M Cully","year":"2022","unstructured":"Cully M. A Tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022;21(1):3\u20135. https:\/\/doi.org\/10.1038\/d41573-021-00202-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1439_CR14","unstructured":"Food US, Drug Administration FDA. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults, 2021, December 23. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"1439_CR15","unstructured":"Food US, Drug Administration FDA. Fact sheet for healthcare providers: emergency use authorization for Molnupiravir, 2024, January 14. (https:\/\/www.fda.gov\/media\/155054\/download) (PDF)."},{"key":"1439_CR16","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1007\/s00216-023-04811-7","volume":"415","author":"I Bartels","year":"2023","unstructured":"Bartels I, Jaeger M, Schmidt TC. Determination of antiSARSCoV-2 virustatic pharmaceuticals in the aquatic environment using highperformance liquid chromatography highresolution mass spectrometry. Anal Bioanal Chem. 2023;415:5365\u201377. https:\/\/doi.org\/10.1007\/s00216-023-04811-7.","journal-title":"Anal Bioanal Chem"},{"key":"1439_CR17","doi-asserted-by":"publisher","first-page":"111178","DOI":"10.1016\/j.microc.2024.111178","volume":"205","author":"EA Ghozzy","year":"2024","unstructured":"Ghozzy EA, El-Enany NM, Tolba MM, Abo El Abass S. Rapid and ecofriendly ultra performance liquid chromatographic analytical methodology for the simultaneous determination of four drugs included in COVID-19 treatment protocol. Microchem J. 2024;205:111178. https:\/\/doi.org\/10.1016\/j.microc.2024.111178.","journal-title":"Microchem J"},{"key":"1439_CR18","doi-asserted-by":"publisher","first-page":"110292","DOI":"10.1016\/j.microc.2024.110292","volume":"200","author":"SM Aboelghar","year":"2024","unstructured":"Aboelghar SM, Hegazy MA, Wagdy HA. Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry. Microchem J. 2024;200:110292. https:\/\/doi.org\/10.1016\/j.microc.2024.110292.","journal-title":"Microchem J"},{"issue":"14","key":"1439_CR19","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/jssc.202200178","volume":"45","author":"RE Saraya","year":"2022","unstructured":"Saraya RE, Deeb SE, Salman BI, Ibrahim AE. Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of Molnupiravir, favipiravir, and Ritonavir in pure forms and pharmaceutical formulations. J Sep Sci. 2022;45(14):2582\u201390. https:\/\/doi.org\/10.1002\/jssc.202200178.","journal-title":"J Sep Sci"},{"issue":"20","key":"1439_CR20","doi-asserted-by":"publisher","first-page":"e202400508","DOI":"10.1002\/slct.202400508","volume":"9","author":"MS Nasr","year":"2024","unstructured":"Nasr MS, Talaat W, Kaddah MMY, Omran G, Morshedy S. Eco-Friendly analytical approaches for the quantification of molnupiravir and favipiravir using capillary zone electrophoresis and derivative ratio spectrophotometry. ChemistrySelect. 2024;9(20):e202400508. https:\/\/doi.org\/10.1002\/slct.202400508.","journal-title":"ChemistrySelect"},{"key":"1439_CR21","doi-asserted-by":"publisher","first-page":"111197","DOI":"10.1016\/j.microc.2024.111197","volume":"205","author":"HM Marzouk","year":"2024","unstructured":"Marzouk HM, Gouda AS, Rezk MR, Abdel-Megied AM. Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure Elucidation. Microchem J. 2024;205:111197. https:\/\/doi.org\/10.1016\/j.microc.2024.111197.","journal-title":"Microchem J"},{"key":"1439_CR22","doi-asserted-by":"publisher","first-page":"109815","DOI":"10.1016\/j.microc.2023.109815","volume":"197","author":"HM Marzouk","year":"2024","unstructured":"Marzouk HM, Gouda AS, Rezk MR, Abdel-Megied AM. A validated LC-MS\/MS method for determination of molnupiravir and favipiravir in human plasma; assessment of the remarkable potential synergistic effect against SARS-CoV-2 infection: application to a Pharmacokinetic study in healthy Egyptian volunteers. Microchem J. 2024;197:109815. https:\/\/doi.org\/10.1016\/j.microc.2023.109815.","journal-title":"Microchem J"},{"issue":"1","key":"1439_CR23","doi-asserted-by":"publisher","first-page":"017502","DOI":"10.1149\/1945-7111\/ad1b7a","volume":"171","author":"ME Nejad","year":"2024","unstructured":"Nejad ME. Simultaneous electrochemical quantification of favipiravir and molnupiravir as antiviral drugs for the treatment of COVID-19 by using a glassy carbon electrode modified by Pd\/Co-Mn-MOF-74. Electrochem. Soc. 2024;171(1):017502. https:\/\/doi.org\/10.1149\/1945-7111\/ad1b7a.","journal-title":"Soc"},{"issue":"8","key":"1439_CR24","doi-asserted-by":"publisher","first-page":"e4837","DOI":"10.1002\/bio.4837","volume":"39","author":"MS ElSherbiny","year":"2024","unstructured":"ElSherbiny MS, Eid SM, Kelani KM, Abdel Ghany MF, El-Olemy A, Hasan MA, Abbas MM. An ultrasensitive green synchronous factorized spectrofluorimetric approach for the simultaneous determination of favipiravir and Molnupiravir: application to pharmaceutical, environmental, and biological matrices. J Lumin. 2024;39(8):e4837. https:\/\/doi.org\/10.1002\/bio.4837.","journal-title":"J Lumin"},{"issue":"7","key":"1439_CR25","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3390\/molecules27072330","volume":"27","author":"YA Sharaf","year":"2022","unstructured":"Sharaf YA, El Deeb S, Ibrahim AE, Al-Harrasi A, Sayed RA. Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of molnupiravir and favipiravir as a novel combined COVID-19 antiviral regimen. Mol. 2022;27(7):2330. https:\/\/doi.org\/10.3390\/molecules27072330.","journal-title":"Mol"},{"issue":"2","key":"1439_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/03602532.2024.2326415","volume":"56","author":"MS Hoseininezhad-Namin","year":"2024","unstructured":"Hoseininezhad-Namin MS, Rahimpour E, Jouyban A. Favipiravir, Remdesivir, and Lopinavir: metabolites, degradation products and their analytical methods. Drug Metab Rev. 2024;56(2):127\u201344. https:\/\/doi.org\/10.1080\/03602532.2024.2326415.","journal-title":"Drug Metab Rev"},{"key":"1439_CR27","doi-asserted-by":"publisher","first-page":"113935","DOI":"10.1016\/j.jpba.2021.113935","volume":"196","author":"K Habler","year":"2021","unstructured":"Habler K, Br\u00fcgel M, Teupser D, Liebchen U, Scharf C, Sch\u00f6nermarck U, Vogeser M, Paal M. Simultaneous quantification of seven repurposed COVID-19 drugs Remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, Lopinavir, Ritonavir, favipiravir and Azithromycin by a two-dimensional isotope Dilution LC\u2013MS\/MS method in human serum. J Pharma Biomed Anal. 2021;196:113935. https:\/\/doi.org\/10.1016\/j.jpba.2021.113935.","journal-title":"J Pharma Biomed Anal"},{"key":"1439_CR28","doi-asserted-by":"publisher","first-page":"109334","DOI":"10.1016\/j.microc.2023.109334","volume":"194","author":"RA Sayed","year":"2023","unstructured":"Sayed RA, Mohamed AR, Shalaby A, Ibrahim H. Innovative micellar-UPLC approach for concomitant determination of favipiravir and Remdesivir with four co-administered cardiovascular drugs in their pharmaceuticals and spiked plasma: greenness and whiteness assessment. Microchem J. 2023;194:109334. https:\/\/doi.org\/10.1016\/j.microc.2023.109334.","journal-title":"Microchem J"},{"key":"1439_CR29","doi-asserted-by":"publisher","first-page":"1022605","DOI":"10.3389\/fmed.2023.1022605","volume":"10","author":"Y Harahap","year":"2023","unstructured":"Harahap Y, Noer RF, Simorangkir TPH. Development and validation of method for analysis of favipiravir and Remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography\u2013tandem mass spectrophotometry. Frontiers in medicine, sec. Infect Diseases: Pathogenesis Therapy. 2023;10:1022605. https:\/\/doi.org\/10.3389\/fmed.2023.1022605.","journal-title":"Infect Diseases: Pathogenesis Therapy"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"107580","DOI":"10.1016\/j.microc.2022.107580","volume":"179","author":"AA Emam","year":"2022","unstructured":"Emam AA, Abdelaleem EA, Abdelmomen EH, Abdelmoety RH, Abdelfatah RM. Rapid and ecofriendly UPLC quantification of Remdesivir, favipiravir and dexamethasone for accurate therapeutic drug monitoring in Covid-19 patient\u2019s plasma. Microchem J. 2022;179:107580. https:\/\/doi.org\/10.1016\/j.microc.2022.107580.","journal-title":"Microchem J"},{"issue":"8","key":"1439_CR31","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1002\/cem.3548","volume":"38","author":"AF Abdel Hakiem","year":"2024","unstructured":"Abdel Hakiem AF, Boushra JM, Noureldeen DAM, Lashien AS, Attia TZ. Response surface experimental design for simultaneous chromatographic determination of two antiviral agents favipiravir and Remdesivir in pharmaceuticals and spiked plasma samples. J Chemom. 2024;38(8):e3548. https:\/\/doi.org\/10.1002\/cem.3548.","journal-title":"J Chemom"},{"key":"1439_CR32","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.microc.2021.107101","volume":"174","author":"DAM Noureldeen","year":"2022","unstructured":"Noureldeen DAM, Boushra JM, Lashien AS, Hakiem AFA, Attia TZ. Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs Remdesivir and favipiravir: green assessment with application to pharmaceutical formulations and human plasma. Microchem J. 2022;174:107101. https:\/\/doi.org\/10.1016\/j.microc.2021.107101.","journal-title":"Microchem J"},{"issue":"5","key":"1439_CR33","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s10895-022-02998-z","volume":"32","author":"M El-Awady","year":"2022","unstructured":"El-Awady M, Elmansi H, Belal F, Shabana R. Insights on the quantitative concurrent Fluorescence-Based analysis of Anti-COVID-19 drugs Remdesivir and favipiravir. J Fluoresc. 2022;32(5):1941\u20138. https:\/\/doi.org\/10.1007\/s10895-022-02998-z.","journal-title":"J Fluoresc"},{"key":"1439_CR34","doi-asserted-by":"publisher","first-page":"121625","DOI":"10.1016\/j.saa.2022.121625","volume":"281","author":"S Ramzy","year":"2022","unstructured":"Ramzy S, Abdelazim AH, Osman AO, Hasan MA. Spectrofluorimetric quantitative analysis of favipiravir, Remdesivir and hydroxychloroquine in spiked human plasma. Spectrochim Acta Mol Biomol Spectrosc. 2022;281:121625. https:\/\/doi.org\/10.1016\/j.saa.2022.121625.","journal-title":"Spectrochim Acta Mol Biomol Spectrosc"},{"issue":"1","key":"1439_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13065-023-00967-6","volume":"17","author":"AS Batubara","year":"2023","unstructured":"Batubara AS, Abdelazim AH, Almrasy AA, Gamal M, Ramzy S. Quantitative analysis of two COVID-19 antiviral agents, favipiravir and Remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation. BMC Chem. 2023;17(1):58. https:\/\/doi.org\/10.1186\/s13065-023-00967-6.","journal-title":"BMC Chem"},{"key":"1439_CR36","doi-asserted-by":"publisher","first-page":"122070","DOI":"10.1016\/j.saa.2022.122070","volume":"287","author":"HS Elama","year":"2023","unstructured":"Elama HS, Zeid AM, Shalan SM, El-Shabrawy Y, Eid MI. Eco-friendly spectrophotometric methods for determination of Remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment. Spectrochim Acta Mol Biomol Spectrosc. 2023;287:122070. https:\/\/doi.org\/10.1016\/j.saa.2022.122070.","journal-title":"Spectrochim Acta Mol Biomol Spectrosc"},{"issue":"1","key":"1439_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13065-023-01001-5","volume":"17","author":"MS Imam","year":"2023","unstructured":"Imam MS, Abdelazim AH, Ramzy S, Batubara AS, Gamal M, Abdelhafiz S, Zeid AM. Adjusted green spectrophotometric determination of favipiravir and Remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models. BMC Chem. 2023;17(1):89. https:\/\/doi.org\/10.1186\/s13065-023-01001-5.","journal-title":"BMC Chem"},{"key":"1439_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka A, Migaszewski ZM, Konieczka P, Nami\u00e9snik J. Analytical Eco-Scale for assessing the greenness of analytical procedures. Trends Anal Chem. 2012;37:61\u201372. https:\/\/doi.org\/10.1016\/j.trac.2012.03.013.","journal-title":"Trends Anal Chem"},{"key":"1439_CR39","doi-asserted-by":"publisher","unstructured":"Mansour FR, P\u0142otka-Wasylka J, Locatelli M, Modified GAPI. (MoGAPI) Tool and Software for the Assessment of Method Greenness: Case Studies and Applications. Analytica. 2024;5:451-7. https:\/\/doi.org\/10.3390\/analytica5030030","DOI":"10.3390\/analytica5030030"},{"issue":"14","key":"1439_CR40","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE-analytical greenness metric approach and software. Anal Chem. 2020;92(14):10076\u201382. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887.","journal-title":"Anal Chem"},{"issue":"1","key":"1439_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.18231\/j.jpbs.2021.002","volume":"9","author":"RN Kulkarni","year":"2021","unstructured":"Kulkarni RN, Pandhare RB, Deshmukh VK, Mohite PB, Pawar AR. High-performance thin layer chromatography: A powerful analytical technique in pharmaceutical drug discovery (review article). J Pharm Bio Sci. 2021;9(1):7\u201314. https:\/\/www.ipinnovative.com\/open-access-journals.","journal-title":"J Pharm Bio Sci"},{"issue":"6","key":"1439_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.20959\/wjpr20216-20560","volume":"10","author":"A Pallavi","year":"2021","unstructured":"Pallavi A, Bala KP, Srinivasa RY, Varaprasada RK, Deepthi R. Instrumentation and future prospects of HPTLC- A review. World J Pharm Res. 2021;10(6):650\u201361. https:\/\/doi.org\/10.20959\/wjpr20216-20560.","journal-title":"World J Pharm Res"},{"key":"1439_CR43","doi-asserted-by":"publisher","first-page":"103595","DOI":"10.1016\/j.ebiom.2021.103595","volume":"72","author":"R Abdelnabi","year":"2021","unstructured":"Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, Vangeel L, Breuer J, Pang J, Williams R, et al. The combined treatment of molnupiravir and favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine. 2021;72:103595.","journal-title":"EBioMedicine"},{"key":"1439_CR44","unstructured":"Colin FP. -The essence of chromatography\u2013 Chap. 6: Thin-Layer chromatography. Elsevier Science & Technology; 2003. pp. 523\u20135."},{"issue":"1","key":"1439_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.30721\/fsab2020.v3.i1.76","volume":"3","author":"S Akterian","year":"2020","unstructured":"Akterian S. Evaluating the vapour evaporation from the surface of liquid pure organic solvents and their mixtures. Food Sci App Biotech. 2020;3(1):77\u201384. https:\/\/doi.org\/10.30721\/fsab2020.v3.i1.76.","journal-title":"Food Sci App Biotech"},{"key":"1439_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-642-14025-9","volume-title":"High-performance Thin-layer chromatography (HPTLC)","author":"PS Variyar","year":"2011","unstructured":"Variyar PS, Chatterjee S, Sharma A. Fundamentals and theory of HPTLC-based separation. In: Srivastava M, editor. High-performance Thin-layer chromatography (HPTLC). Berlin, Germany: Springer; 2011. pp. 27\u201340. https:\/\/doi.org\/10.1007\/978-3-642-14025-9."},{"key":"1439_CR47","unstructured":"ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures Q2(R2); International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Geneva, Switzerland. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf"},{"key":"1439_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.talanta.2011.11.048","volume":"88","author":"II Hewala","year":"2012","unstructured":"Hewala II, Bedair MM, Shousha SM. New concept for HPTLC peak purity assessment and identification of drugs in multi-component mixtures. Talanta. 2012;88:623\u201330. https:\/\/doi.org\/10.1016\/j.talanta.2011.11.048.","journal-title":"Talanta"},{"key":"1439_CR49","unstructured":"Miller JN, Miller JC. Statistics and Chemometrics for Analytical Chermistry, 5th edition, Pearson Education Limited, Harlow, England, 2005;54\u201361."},{"key":"1439_CR50","doi-asserted-by":"publisher","first-page":"110733","DOI":"10.1016\/j.microc.2024.110733","volume":"201","author":"NM Habib","year":"2024","unstructured":"Habib NM, Tony RM, AlSalem HS, Algethami FK, Gamal M. Evaluation of the greenness, whiteness, and blueness profiles of stability indicating HPLC method for determination of Denaverine hydrochloride and benzyl alcohol in pharmaceuticals. Microchem J. 2024;201:110733. https:\/\/doi.org\/10.1016\/j.microc.2024.110733.","journal-title":"Microchem J"},{"key":"1439_CR51","doi-asserted-by":"publisher","first-page":"100709","DOI":"10.1016\/j.scp.2022.100709","volume":"28","author":"DS El-Kafrawy","year":"2022","unstructured":"El-Kafrawy DS, Abo-Gharam AH, Abdel-Khalek MM, Belal TS. Comparative study of two versatile multi-analyte chromatographic methods for determination of diacerein together with four non-steroidal anti-inflammatory drugs: greenness appraisal using analytical Eco-Scale and AGREE metrics. Sust Chem Pharm. 2022;28:100709. https:\/\/doi.org\/10.1016\/j.scp.2022.100709.","journal-title":"Sust Chem Pharm"},{"issue":"2","key":"1439_CR52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.21608\/japs.2024.286224.1022","volume":"1","author":"DS El-Kafrawy","year":"2024","unstructured":"El-Kafrawy DS, Abo-Gharam AH, Abdel-Khalek MM, Belal TS. Two eco-friendly spectrophotometric methods for the concurrent Estimation of diacerein and meloxicam: greenness and whiteness assessment. J Adv Pharm Sci. 2024;1(2):86\u201399. https:\/\/doi.org\/10.21608\/japs.2024.286224.1022.","journal-title":"J Adv Pharm Sci"},{"key":"1439_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/D0AY02169E","volume":"13","author":"M Gamal","year":"2021","unstructured":"Gamal M, Naguib IA, Panda DS, Abdallah FF. Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. Anal Meth. 2021;13:369\u201380. https:\/\/doi.org\/10.1039\/D0AY02169E.","journal-title":"Anal Meth"},{"key":"1439_CR54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s43094-024-00746-7","volume":"10","author":"P Prajapati","year":"2024","unstructured":"Prajapati P, Patel P, Naik D, Haque A, Shah S. Red, green, and blue model assessment and AQbD approach to HPTLC method for concomitant analysis of Metformin, Pioglitazone, and teneligliptin. Future J Pharm Sci. 2024;10:169. https:\/\/doi.org\/10.1186\/s43094-024-00746-7.","journal-title":"Future J Pharm Sci"},{"issue":"19","key":"1439_CR55","doi-asserted-by":"publisher","first-page":"2300332","DOI":"10.1002\/jssc.202300332","volume":"46","author":"P Prajapati","year":"2023","unstructured":"Prajapati P, Dixit V, Pulusu VS, Chauhan R, Shah S. Green analytical chemistry-driven response surface modeling to stability-indicating chromatographic method for Estimation of cilnidipine and application of high-performance thin-layer chromatography\u2013mass spectrometry for characterization of degradation products. J Sep Sci. 2023;46(19):2300332. https:\/\/doi.org\/10.1002\/jssc.202300332.","journal-title":"J Sep Sci"},{"issue":"5","key":"1439_CR56","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/jaoacint\/qsac056","volume":"105","author":"P Prajapati","year":"2022","unstructured":"Prajapati P, Tailor P, Shahi A, Acharya A, Shah S. Application of chemometry and design of experiments to green HPTLCMethodfor synchronous Estimation of multiple FDCs of cilnidipine. J AOAC INT. 2022;105(5):1491\u2013501. https:\/\/doi.org\/10.1093\/jaoacint\/qsac056.","journal-title":"J AOAC INT"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01439-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:28:04Z","timestamp":1757147284000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01439-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01439-9","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}